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The Silkworm-Baculovirus (sb) expression system for recombinant
proteins has several advantages over E. coli, e.g., increased yield,
improved solubility and incorporation of post-translational modifications
(e.g., glycosylation). A novel prothrombin time reagent (sbPT, Sysmex
Corporation. Japan) has been developed using recombinant human tissue
factor produced by this system (Fig. 1).
Fig. 1Protein 
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The recombinant transfer
vector is co-transfected
with the baculovirus DNA
into silkworm cells (BmN).
The recombinant 
baculovirus is injected into 
a larva or pupa. The  
hemolymph or tissue are 
harvested. The protein is  
purified from soluble 
fractions using standard 
chromatography columns.
INR values for 130 plasma samples from patients receiving warfarin
showed good agreement between methods (Figures 2 and 3; mean
INR 3.06; 3.09 and 3.02 for sbPT, PTA and PTB respectively. Most INR
were within 0.5 INR units (99% for PTA and 96% for PTB). All three PT
methods exhibited similar sensitivity to FII deficiency, while sbPT was
more sensitive to deficiencies of FV, FVII and FX and coagulation
defects in liver disease.
The aim of this study was to compare the performance of sbPT with two
widely used PT reagents.
The performance of sbPT was compared to two commercial PT reagents
containing either human placental thromboplastin (PTA) or recombinant
human TF (PTB) on a Sysmex CS-5100 coagulometer, using instrument-
specific ISI (1.00, 1.07 and 0.97 for sbPT, PTA and PTB respectively). On-
board stability and imprecision were assessed using commercial QC
preparations. Comparability testing was performed on over 300 normal
and abnormal plasma samples.
sbPT demonstrated excellent levels of imprecision (Table 1) and on-board
stability (less than 2.2% variation over 4 days). Normal reference ranges
of 9.8 – 12.8s (sbPT), 10.4 – 13.6s (PTA) and 9.6 – 11.5s (PTB) were
established in plasmas from 100 normal healthy donors.
Table 1. Between day imprecision
Heparin interference was not detected by sbPT or PTB (both of
which contain a heparin neutralising compound) at levels up to 1.5
IU/mL. All three reagents had similar sensitivity to lupus
anticoagulant. sbPT demonstrated dose responsiveness to
Rivaroxaban, Dabigatran and Apixaban and with steeper response
curves than PTA or PTB.
Fig. 2.  INR values for normal controls (n = 100)  and patients receiving warfarin 
(n = 130). PTA vs sbPT
Fig. 2.  INR values for normal controls (n = 100) and patients receiving 
warfarin (n = 130). PTB vs sbPT
In a wide range of plasma samples, sbPT demonstrated
comparable or improved performance relative to two
commercial PT reagents which are suitable for the control of
oral vitamin K antagonist therapy and the detection of
congenital or acquired deficiency of FII, FV, FVII and FX.
